These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24036604)

  • 1. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.
    Simioni C; Martelli AM; Cani A; Cetin-Atalay R; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2013 Sep; 4(9):1496-506. PubMed ID: 24036604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
    Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
    Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
    Ji D; Zhang Z; Cheng L; Chang J; Wang S; Zheng B; Zheng R; Sun Z; Wang C; Zhang Z; Liu R; Zhang X; Liu X; Wang X; Li J
    PLoS One; 2014; 9(1):e85116. PubMed ID: 24416349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
    Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
    Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
    Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
    Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
    Cheng Y; Zhang Y; Zhang L; Ren X; Huber-Keener KJ; Liu X; Zhou L; Liao J; Keihack H; Yan L; Rubin E; Yang JM
    Mol Cancer Ther; 2012 Jan; 11(1):154-64. PubMed ID: 22057914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth.
    Lai WT; Cheng KL; Baruchello R; Rondanin R; Marchetti P; Simoni D; Lee RM; Guh JH; Hsu LC
    Biochem Pharmacol; 2016 Aug; 113():12-23. PubMed ID: 27328368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
    Simioni C; Cani A; Martelli AM; Zauli G; Alameen AA; Ultimo S; Tabellini G; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Jul; 6(19):17147-60. PubMed ID: 26003166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
    Rebecca VW; Massaro RR; Fedorenko IV; Sondak VK; Anderson AR; Kim E; Amaravadi RK; Maria-Engler SS; Messina JL; Gibney GT; Kudchadkar RR; Smalley KS
    Pigment Cell Melanoma Res; 2014 May; 27(3):465-78. PubMed ID: 24490764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
    Fei M; Lu M; Wang Y; Zhao Y; He S; Gao S; Ke Q; Liu Y; Li P; Cui X; Shen A; Cheng C
    Med Oncol; 2009; 26(2):178-85. PubMed ID: 18937079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
    Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
    PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.